Table 1.
Demographic characteristics of patients with atypical glandular cells with and without concurrent squamous cell abnormalities.
| Characteristic | AGC + Sq | AGC- Alone | P-vaule |
|---|---|---|---|
| Age, y | 48.22 ± 12.79 | 45.25 ± 10.87 | 0.032 |
| Age distribution, y | <0.0001 | ||
| <25 | 0 | 7/974 (0.7%) | |
| 25-39 | 15/54 (27.8%) | 294/974 (30.2%) | |
| 40-65 | 30/54 (55.6%) | 614/974 (63.0%) | |
| >65 | 9/54 (16.7%) | 59/974 (6.1%) | |
| AGC subtype, n/N (%) | <0.0001 | ||
| AEM | 9/54 (16.7%) | 237/974 (24.3%) | |
| AEC | 14/54 (25.9%) | 275/974 (28.2%) | |
| AGC-NOS | 9/54 (16.7%) | 368/974 (37.8%) | |
| AGC-FN | 22/54 (40.7%) | 94/974 (9.7%) | |
| HPV status, n/N (%) | 0.078 | ||
| Positive | 12/43 (27.9%) | 131/756 (17.3%) | |
| Negative | 31/43 (72.1%) | 625/756 (82.7%) | |
| HPV type, n/N (%) | 0.258 | ||
| 16+ | 3/12 (25.0%) | 29/131 (22.1%) | |
| 18+ | 1/12 (8.3%) | 21/131 (16.0%) | |
| Other hrHPV+ | 7/12 (58.3%) | 80/131 (61.1%) | |
| 16+, 18+ | 1/12 (8.3%) | 1/131 (0.8%) | |
| Histopathological Outcome | <0.0001 | ||
| Negative/Benign lesion | 30/43 (69.8%) | 617/726 (85.0%) | |
| Premalignancy | 4/43 (9.3%) | 39/726 (5.4%) | |
| Malignancy | 9/43 (20.9%) | 70/726 (9.6%) | |
| Histopathological Outcome | 0.001 | ||
| Benign | 19/43 (44.2%) | 409/726 (56.3%) | |
| Gl A | 10/43 (23.3%) | 208/726 (28.7%) | |
| Sq A | 11/43 (25.6%) | 106/726 (14.6%) | |
| Gl A and Sq A | 3/43 (7.0%) | 3/726 (0.4%) | |
AEC: atypical endocervical cells; AEM: atypical endometrial cells; AGC, atypical glandular cell; AGC + Sq, atypical glandular cells with concurrent squamous cell abnormalities; AGC-alone, atypical glandular cells without concurrent squamous cell abnormalities; AGC-NOS: atypical glandular cells, not otherwise specified; AGC-FN: atypical glandular cells, favor neoplastic; Gl A and Sq A, glandular abnormalities and squamous abnormalities; HPV, human papillomavirus.